Hofseth BioCare ASA

Equities

HBC

NO0010598683

Food Processing

Market Closed - Oslo Bors 10:45:00 2024-04-24 am EDT 5-day change 1st Jan Change
2.2 NOK +0.46% Intraday chart for Hofseth BioCare ASA +4.76% -16.03%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hofseth BioCare ASA Announces Board Changes CI
Hofseth BioCare ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Hofseth BioCare ASA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hofseth BioCare ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Hofseth BioCare ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Hofseth BioCare Secures Seed Funding for Pre-clinical Study of Prostate Cancer Treatment MT
Aqua Bio Technology Asa Announces Distribution Agreement with Hofseth Biocare Asa CI
Hofseth Biocare ASA Announces the Online Publication of Its Abstract CI
Norway’s Hofseth Biocare Moves Prostate Cancer Co-treatment Project to US Entity MT
Hofseth BioCare ASA Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hofseth BioCare ASA Auditor Raises 'Going Concern' Doubt CI
Hofseth BioCare ASA Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hofseth BioCare ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Hofseth BioCare ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Hofseth BioCare Says Preclinical Trial Shows ProGo Peptides Support Gut Health MT
Hofseth BioCare ASA's Progo Bioactive Peptides Now Is A "New Dietary Ingredient" for the US FDA CI
Hofseth BioCare ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Hofseth Biocare Appoints CFO as CEO MT
Hofseth BioCare ASA Announces Executive Changes CI
Hofseth BioCare ASA announced that it has received NOK 1.4196 billion in funding CI
Hofseth BioCare ASA Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Hofseth BioCare ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021 CI
Hofseth BioCare ASA Approves Election Amy Novogratz to Its Board of Directors CI
Hofseth Biocare Gets US Dietary Ingredient Status for Nutritional Suplements Extracted from Salmon MT
Hofseth Biocare ASA Successfully Receive New Dietary Ingredient Status from the US FDA CI
Chart Hofseth BioCare ASA
More charts
Hofseth Biocare ASA is a Norway-based biotech company that offers ingredients and finished products for humans and animals. The Company’s business is development, manufacturing, marketing and sale of marine ingredients such as oil, calcium and protein products. Its main products are Salmon protein hydrolysate (ProGo), which is a protein for sports, endurance, and recovery powders; Fresh, all-natural salmon oil (OmeGo) that has a full spectrum of omega fatty acids, including EPA, DHA and DPA, totaling 21 different fatty acids; Calcium bone powder (CalGo) is a natural marine collagenic bone powder and CollaGo is a Collagen Peptide powder optimised to improve the beauty of hair, skin and nails. Hofseth BioCare's headquarters are in Aalesund with branches in Oslo, Chicago, Mumbai, Tokyo and Menlo Park, California.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. HBC Stock
  4. News Hofseth BioCare ASA
  5. Hofseth BioCare : Signs Distribution Agreement For Marine Branded Products